Beam reports $1.25B cash, FDA alignment on BEAM-302 accelerated path; risto-cel BLA expected year-end 2026

Beam Therapeutics Inc.

Estimated $1.25B cash, cash equivalents and marketable securities as of Dec 31, 2025; operating runway extended into 2029.
FDA alignment on potential accelerated approval for BEAM-302 based on AAT biomarkers over 12 months; ~50 additional patients to be enrolled.
BLA submission for risto-cel (formerly BEAM-101) expected as early as year-end 2026; BEACON trial fully enrolled, manufacturing done December 2025.
Updated BEAM-302 Phase 1/2 data and pivotal plan expected by end of Q1 2026; new liver-targeted program to be announced H1 2026.
Initial BEAM-301 clinical data expected in 2026; BEAM-103 Phase 1 healthy volunteer trial to complete dosing in H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.